Berenberg upgrades Eli Lilly to Buy after obesity-drug demand surge
Berenberg upgraded Eli Lilly to Buy from Hold, citing accelerating obesity-drug demand that could lead to results above the company’s ambitious 2026 outlook. Analyst Kerry Holford also raised her price target.